COVAXIN

Covid-19 vaccine now available in India for kids aged 5-12

DCGI clears emergency use of Covaxin for kids aged above 6 and Corbevax for those above 5; Zydus Cadila’s ZyCov-D gets approval for children aged 12 or more   New Delhi: Expanding the reach of the Covid-19 vaccination programme in the country, the Drugs Controller General of India (DCGI) on Tuesday gave emergency use approval...

Covaxin, Covishield prices slashed; to cost Rs 225 per dose

New Delhi: A day before the Covid-19 booster dose is made available for adults at private vaccination centres, the prices of both Covaxin and Covishield were brought down. Both the Covid-19 vaccines will now cost Rs 225 per dose. Serum Institute of India manufactures Covishield in India while Covaxin is manufactured by Bharat Biotech. SII...

More doors open for Covaxin; UK to allow fully vaccinated travellers from November 22

New Delhi: The emergency approval to Covaxin by the World Health Organization (WHO) has opened more doors for those who have received the vaccine. After the United States, now the United Kingdom (UK) too has given the nod to Bharat Biotech’s indigenously developed Covid-19 vaccine. Thus, those who have received both the shots of Covaxin...

After WHO approval, US to allow fully ‘Covaxin-ated’ travellers from November 8

New Delhi: The approval by the World Health Organization (WHO) for India’s indigenous Covid-19 vaccine Covaxin for emergency use has ended the uncertainty among those who had got both doses of the vaccine but were unable to travel in absence of the approval. Bharat Biotech’s Covaxin got the WHO approval on Wednesday. Following this, the...

Fully ‘Covaxin-ated’, but want Covishield to travel abroad? Let’s wait for WHO decision, says SC

New Delhi: The delayed approval to Bharat Biotech’s Covid-19 vaccine Covaxin by the World Health Organization (WHO) has meant many an anxious moment for several individuals who have received it and are unable to travel to certain countries because of lack of approval to Covaxin. A petition in the Supreme Court had sought permission for...

Mansukh Mandaviya releases first batch of Covaxin from Bharat Biotech’s Gujarat facility

Union health minister Mansukh Mandaviya on Sunday released the first commercial batch of Covaxin from Chiron Behring Vaccines facility of Bharat Biotech in Gujarat’s Ankleshwar. Notably, Covaxin, developed by Bharat Biotech, is one of the COVID-19 vaccines approved by the Indian drug regulator for emergency use. Covaxin combined with Serum Institute’s Covishield forms the...

Vaccine for children by August? Health minister Mansukh Mandaviya says so

New Delhi: Newly appointed Union health minister Mansukh Mandaviya has said that Covid-19 vaccine for children could be available by as early as next month. Mandaviya said this at the BJP Parliamentary meeting held in New Delhi on Tuesday morning. Earlier, AIIMS chief Dr Randeep Guleria had said that the results of the trials of...

Brazil suspends Covaxin deal worth $324 million over allegations of irregularities

As per the deal, Bharat Biotech was to supply 20 million doses of the Covid-19 vaccine Brasilia: In wake of allegations of irregularities, the Brazilian government has suspended a $324 million contract with Bharat Biotech for purchase of its Covid-19 vaccine ‘Covaxin’. The deal for purchase of 20 million doses of the vaccine had been...

Top US institute says Covaxin effective against Delta variant

The US National Institute of Health (NIH) has said that Bharat’s Biotech’s vaccine against COVID-19 ‘Covaxin’ effectively neutralizes the Alpha and Delta variants of coronavirus. The NIH statement is based on two studies. It said the results of two studies of blood serum from people who had received Covaxin suggests that the vaccine generates antibodies...

‘Not paid a cent’: Brazil president Bolsonaro clarifies amid controversy over Covaxin deal

Brasilia: Amid the ongoing controversy over purchase of India-made Covaxin by Brazil, the country’s President Jair Bolsonaro has said that no money has been paid for and no receipt made of the vaccine. The controversy relates to a contract signed by Brazil for 20 million doses of Bharat Biotech’s Covaxin, worth $320 milion. The prosecutor-general’s...

Covaxin found 77.8% effective in protecting against COVID-19 in phase 3 trials

Hyderabad-based vaccine maker Bharat Biotech’s COVID-19 vaccine ‘Covaxin’ has been found to be 77.8 per cent effective in protecting against the viral infection, according to the phase 3 clinical trial results that have been submitted to the Drugs Controller General of India (DCGI). The phase 3 trial involved 25,800 participants from across the country. The...

Bharat Biotech submits Covaxin’s Phase 3 clinical trial data to DCGI

Vaccine maker Bharat Biotech has submitted the third phase clinical trial data of its vaccine against COVID-19 ‘Covaxin’ to the Drugs Controller General of India (DCGI). The subject expert committee of the regulator is going to meet today to deliberate on the data submitted by the company. On Wednesday, the company is supposed to hold...